Incretins (GLP-1 Receptor Agonists) and Polycystic Ovaries.

JBRA Assist Reprod · 2025

Last updated 2026-05-28

A class of drugs called incretins, or GLP-1 receptor agonists, has shown promise in improving metabolic health for women with polycystic ovary syndrome (PCOS). Studies report benefits such as better blood sugar control, reduced insulin resistance, and lower levels of male hormones, though specific doses or participant counts are not mentioned in the abstract.

AI summary of the abstract below.

Journal	JBRA Assist Reprod, 2025
Citations	0
Molecules	—
Conditions studied	Pcos

Abstract

Polycystic ovary syndrome (PCOS) is a widespread condition affecting women of reproductive age. A new class of medications called incretins (GLP1RAs) provides new opportunities for reducing obesity, hyperandrogenism, and insulin resistance in these patients. Promising results have been achieved, including metabolic improvements and benefits in women with PCOS using different GLP1RAs.

Verbatim abstract via PubMed 41165218 ↗